This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Monday's Health Winners & Losers

Allergan (AGN) and Mentor (MNT) saw their shares jump Monday after both won long battles to start selling silicone-gel breast implants for cosmetic purposes.

Allergan was up 7.7% to $121.20, and Mentor was higher by 10.3% to $52.47.

The Food and Drug Administration cleared the implants late Friday for women at least 22 years old, saying the "extensive body of scientific evidence provides reasonable assurance of the benefits and risks of these devices."

Cyberonics (CYBX) said two top executives, including longtime CEO Robert "Skip" Cummins, have resigned from the company following a probe into past option grants.

Investors were cheering the shakeup, and shares of Cyberonics, the maker of a device for treating depression, jumped 11.2% to $24.

Leaving along with Cummins is Chief Financial Officer Pamela Westbrook. Reese Terry Jr., the company's co-founder, former CEO and a current director, has been named interim chief executive. George Parker III was appointed interim chief operating officer, and John Riccardi has been named interim CFO, effective immediately.

Shares of CoTherix (CTRX) rose 19.5% to $13.38 after Swiss biotech company Actelion agreed to buy it for $420 million.

The deal was unanimously approved by both companies' boards of directors. Actelion will make a cash tender offer of $13.50 for each CoTherix share, representing a 21% premium to the stock's closing price Friday.

Anadys Pharmaceuticals (ANDS) was down 2.3% to $4.26 after it named Dr. Lawrence Fritz as its new president and chief executive.

The appointment is part of a transition plan announced in June. Fritz will replace Dr. Kleanthis Xanthopoulos, who is also a co-founder of the cancer and antiviral drugmaker. Xanthopoulos, who has served as president and CEO since the company's inception in May 2000, will continue to serve as a member of the board of directors.

The chief operating officer of drug developer SciClone Pharmaceuticals (SCLN) has stepped down from his post, the company announced. Shares of SciClone lost 2.1% to $2.74.

Alfred Rudolph, who joined the company in 1997, left last Friday. Friedhelm Blobel, the company's president and CEO, will take on the COO duties.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs